Reviews/Giant Cell Arteritis/Upadacitinib induces remission
Emerging · GCA-EMRG-01 · v2
One large, well-run randomized trial tested upadacitinib against placebo in people with giant cell arteritis, measuring whether patients stayed free of disease signs and symptoms through one year while tapering off steroids [1]. At the 15 mg dose, more patients reached this sustained-remission goal than on placebo, and the drug also beat placebo on a set of carefully pre-planned secondary measures [1]. The lower 7.5 mg dose did not beat placebo, so the benefit held only for the higher dose [1]. Just under half of treated patients reached the goal, so a majority still did not, and the trial followed patients only to one year [1]. There is no second trial of upadacitinib in this disease in the evidence here, so the finding rests on a single sponsor-funded study [1].
The corpus contains one directly on-claim study: SELECT-GCA, a phase 3 randomized, double-blind, placebo-controlled trial of 428 patients [1]. Upadacitinib 15 mg achieved sustained remission at week 52 in 46.4% versus 29.0% on placebo (P = 0.002) and was superior across a multiplicity-controlled hierarchy of secondary endpoints [1]. The 7.5 mg dose was not superior to placebo on the primary endpoint [1]. No other paper in the corpus tests upadacitinib in giant cell arteritis; the remaining papers study different drugs in the disease [2, 3, 4] or upadacitinib in other diseases [5, 6, 7, 8]. The contested point: The evidence divides on how far the word 'upadacitinib' and the word 'sustained' can be carried: only the 15 mg dose beat placebo while 7.5 mg did not [1], and 'remission' is a composite clinical-plus-taper endpoint measured to week 52 [1], not a hard vascular outcome or a durability finding beyond one year. The benefit is also sub-majority in absolute terms (46.4% vs 29.0%) [1].
All 8 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Giant Cell Arteritis, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim rests on a single sponsor-funded (AbbVie) phase 3 trial [1] with no independent replication in the corpus, so evidential independence is minimal.
The effect is dose-specific: 15 mg was superior but 7.5 mg was not superior to placebo [1], so the unqualified term 'upadacitinib' overreaches a result confined to one dose.
Where it remains uncertain. The 7.5 mg dose was not superior to placebo [1], the absolute benefit is sub-majority, and the result comes from a single sponsor-funded trial with no replication in this corpus [1].
Aleatory
Even at the effective dose, 46.4% reached sustained remission versus 29.0% on placebo [1], so individual outcome remains variable and a majority of treated patients did not respond.
Epistemic
Only one trial in giant cell arteritis exists in the corpus [1]; no independent study confirms the 15 mg finding, leaving between-study consistency unknown.
Inferential
'Upadacitinib' is used without a dose, but only 15 mg was superior while 7.5 mg was not [1], so inferring a drug-level effect over-extends a dose-specific result.
The load-bearing papers from a corpus of 8, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary evidence that upadacitinib 15 mg induces sustained remission in GCA with statistical superiority over placebo.
“Upadacitinib at a dose of 7.5 mg was not superior to placebo with respect to the primary end point (41.1% [95% CI, 31.8 to 50.4]).”
Panel auditInternal validity: high · scope of inference: Adults with new-onset or relapsing giant-cell arteritis (70% new-onset), sustained remission through week 52 with a 26-week glucocorticoid taper.Key limitations: single trial · 7.5 mg dose not superior to placebo · durability beyond 52 weeks not addressed in abstract
1 of 8 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
One pivotal, adequately powered sponsor-funded phase 3 RCT directly supports the claim for the 15 mg dose, but single-source evidence, a dose-specific effect, and a modest absolute benefit cap confidence at the Likely band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent replication of the 15 mg effect. The claim rests on one sponsor-funded trial [1]; without a second trial the effect's reproducibility is unestablished. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A second, ideally non-sponsor, randomized placebo-controlled trial of upadacitinib 15 mg in giant cell arteritis.
Open question: Does upadacitinib 15 mg produce sustained remission in giant cell arteritis when tested independently of the sponsor? Why it is still open: The only supporting trial in the corpus is AbbVie-funded with no replication [1].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19